July 15, 2021
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Collaborative research with Gunma University to explore
new indications for bendamustine and rigosertib
TOKYO, Japan, July 15, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio")announced today that it has entered into a joint research agreement with Gunma University toexplore new potential indications for bendamustine and rigosertib.
Under the collaboration, SymBio will work with Professor Ken Shirabe, Graduate School of Medicine,Gunma University, and Associate Professor Seshiru Nakazawa, Department of Respiratory Surgery,
Center for Surgery, Gunma University Hospital, to seek new potential uses for the compounds, incombination with each other and with other drugs.
By examining the effects associated with inhibiting the linear ubiquitin chain assembly complex(LUBAC), we will investigate the pharmacological effects of the compounds to explore their potential
application in solid tumors.
Associate Professor Nakazawa has worked to bridge basic research and clinical applications and has
significant research accomplishments in the functional analysis of ubiquitin signals, particularly inthe study of the association between LUBAC activation and various diseases.
The Company, utilizing its experience in obtaining approvals for anticancer drugs in shortened
timelines, will work with Gunma University to explore new indications for the compounds, tocontinue to fulfil its mission to address the unmet medical needs of patients.
Statement of Fuminori Yoshida, President and Chief Executive Officer of SymBio: "Based on LUBAC
inhibitory effect of bendamustine and the mechanism of action of rigosertib, we will explore newtarget indications and the development of new therapeutic methods in collaboration with theGraduate School of Medicine of Gunma University."[Contact]Investor Relations
Tel: +81 (0)3 5472 1125

1About TREAKISYM®
TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug firstused in Germany in the 1970s, is now widely used in more than 50 countries with indications for lowgrade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.
 TREAKISYM® Intravenous Infusion 100 mg was approved in October 2010 for manufacturing andmarketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma andmantle cell lymphoma in Japan.
 TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japanin August 2016.
 TREAKISYM® was approved for the additional indications of first-line treatment of low-grade Bcell non-Hodgkin’s lymphoma and mantle cell lymphoma in Japan in December 2016.
 SymBio achieved the primary endpoint (overall response rate) in Phase 3 study of TREAKISYM® incombination with rituximab as treatment for r/r DLBCL and obtained approval of a partial change
application with respect to its marketing approval in March 2021.
 TREAKISYM® ready-to-dilute (“RTD”) liquid formulation was approved in Japan in September
2020.
 SymBio aims to achieve annual sales of JPY 10 billion on a NHI drug price basis at the earliest
possible stage.
About Rigosertib
Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activationof RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K,
and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus
killing cancer cells. SymBio obtained the development and commercialization licensing rights for
Rigosertib from Onconova in July, 2011 for Japan and Korea.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discoveringand developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes(MDS). Onconova has a pipeline of proprietary targeted agents designed to work against specificcellular pathways that are important in cancer cells. For more information, please visit
https://www.onconova.com.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma
USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio’s
underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading
global specialty biopharmaceutical company dedicated to addressing underserved medical needs.

2